Angelini Ventures is proud to have participated in the recent Series A financing round for COUR Pharmaceuticals, a clinical-stage biotechnology company focused on developing first-in-class, disease-modifying therapies for immune-mediated diseases.

The investment round was co-led by Lumira Ventures and Alpha Wave Ventures, with participation from other prominent strategic investors, including Roche Venture Fund, Pfizer, Bristol Myers Squibb, and the Juvenile Diabetes Research Foundation (JDRF) T1D Fund.

The $105 million in financing raised by COUR will help support the advancement of multiple product candidates, including Phase 2 proof-of-concept clinical studies in myasthenia gravis and type 1 diabetes, in addition to other pipeline opportunities. These product candidates, along with existing Phase 2 partnered programs with Takeda Pharmaceuticals and Ironwood Pharmaceuticals in celiac disease and primary biliary cholangitis, respectively, make COUR a leader in antigen-specific immune tolerance.

As a venture capital firm focused on investing in innovative healthcare startups, Angelini Ventures is excited to support COUR's platform technology and unique approach to restoring self-tolerance safely and more effectively in autoimmune disorders. COUR's proprietary antigen-specific immune tolerance platform is a versatile and first-in-class approach that has the potential to treat a wide range of autoimmune and inflammatory diseases.

Many autoimmune diseases are caused by a reaction of the immune system that attacks healthy cells and tissues that perform important functions. COUR's approach aims to "teach" the immune system to recognize certain molecules it perceives as foreign and dangerous (antigens) to avoid attacking them. The unique nanotechnologies developed by COUR enable the delivery of a large quantity and variety of antigens to the body without toxic effects, increasing the likelihood that the immune system will learn not to attack them. This technology has already shown promising clinical results in the field of celiac disease and primary biliary cholangitis.

Overall, the impressive syndicate of investors and COUR's paradigm-changing potential for patients impacted by a variety of autoimmune diseases made this investment an extremely attractive opportunity for Angelini Ventures. We are dedicated to collaborating with COUR and its partners to help advance these potentially groundbreaking treatments for immune-related diseases and bring life-changing therapies to patients in need.